- Dotz Nano (DTZ) signs a deal with Hygiene Links who’ll get exclusive rights to distribute the Dotz Test Kits in the United Arab Emirates, Egypt and Sudan
- To maintain exclusivity, the Dubai-based company needs to order at least 50,000 units per month for six months for each country
- In light of this, Hygiene Links has made a US$2.1 million (A$2.8 million) purchase order for Dotz Nano to supply the kits for the next six months
- The Dotz Test Kits are used to detect the SARS-CoV-2 virus by taking a saliva-based and nasopharyngeal swab and results are received in less than 17 minutes
- Dotz Nano’s shares are up 7.46 per cent at 36 cents
Dotz Nano (DTZ) has entered a distribution agreement with chemical, plastics and consumables manufacturer, Hygiene Links.
This two-year agreement grants the Dubai-based company the exclusive right to sell the Dotz Test Kits in the UAE, Egypt and Sudan.
Hygiene Links is looking to increase its offering to include health care and personal protective equipment products. The Dotz Test Kits are expected to be one of the first of Hygiene Links’ new product offering.
To maintain exclusivity, Hygiene Links needs to satisfy a minimum order of 50,000 units per month for six months for each country. This equates to at least US$2.1 million (A$2.8 million) for the three countries.
In light of this condition, Hygiene Links has made a US$2.1 million purchase order for Dotz Nano to supply its Dotz Test Kits for the next six months. The products will be shipped monthly with 50 per cent of each shipment fee paid upfront and the other half paid upon delivery.
The Dotz Test Kits are used to detect the SARS-CoV-2 virus by taking a saliva-based and nasopharyngeal swab. Patients get their results in less than 17 minutes which makes this a simple, quick and cost-effective testing method.
These kits have also received CE Mark approval which allows them to be sold in the European Union and to the private sector in the UAE, Egypt and Sudan.
However, there are certain regulatory requirements which need to be satisfied before they can be publicly sold in the UAE, Egypt and Sudan.
Dotz Chairman and interim CEO, Bernie Brookes, was pleased with the distribution deal and to have received a purchase order.
“We believe our virus detection technology is truly industry-leading, providing a method to accurately identify the SARS-CoV-2 virus at scale and in a cost-effective and timely manner,” Mr Brookes said.
“While we are awaiting FDA regulatory approval for the nasopharyngeal swab and saliva-based Dotz Test Kits, our successful clinical trial of the nasopharyngeal swab Dotz Test Kits and CE Mark authorisation has enabled us to start to engage with a number of potential customers.”
The company expects the first kits will be shipped in August this year.
Dotz Nano’s shares were up 7.46 per cent at 36 cents at 3:57 pm AEST.